STO-CSCO Joint Symposium - 2015

BIG Data and Its Impact on Cancer Research and Cancer Patients

Xiamen International Conference & Exhibition Center
Xiamen International Conference & Exhibition Center

September 18, 2015
Xiamen International Conference and Exhibition Center
Xiamen, China

Building on the vibrant partnership of STO and CSCO, we proudly premiered the STO-CSCO Joint Symposium during the 18th Annual CSCO Meeting on September 18th in Xiamen.

BIG Data and Its Impact on Cancer Research and Cancer Patients is a vitally important topic that has been fostered by ultra-fast data processors along with the storage capacity of cloud computing. These technology advances allow us, for the first time, to perform research into vast databases that will allow "New Discoveries from Old Data."

This year's Symposium featured an international faculty of world-class experts who delivered lectures along with a stimulating panel discussion that included audience participation.

Symposium Co-Chairmen

Professor Ding YU, MD,
Director of Medical Oncology,
Hubei Cancer Hospital
Standing Member - Executive Committee, CSCO

Professor Martin J. Murphy,
Convener, STO
Chief Executive Officer,
CEO Roundtable on Cancer


Prof. Ding YU

Director of Medical Oncology, Hubei Cancer Hospital
Standing Member- Executive Committee, CSCO

Prof. YU studied at the medical department of the Tongji Medical University, Wuhan from 1978 to 1983, and worked in the department of medical oncology after graduation. In 20 years as a medical oncologist, he focused on breast cancer, lung cancer, lymphoma, and gastrointestinal cancer and became especially skilled in handling the adverse effects of cancer chemotherapy treatment. In his daily work, he emphasizes communication with cancer patients during chemotherapy and helps to organize scientific educational sessions for patients and their families. Over the past decade he has edited many academic books and has published more than 50 papers in scientific journals.

Martin J. Murphy, DMedSc, PhD, FASCO

Convener, Society for Translational Oncology
Chief Executive Officer, CEO Roundtable on Cancer
North Carolina, USA

Dr. Martin J. Murphy provides strategic support for cancer drug development programs of academic centers, global pharmaceutical and biotechnology companies. He is the Founding Executive Editor of the 20-year-old peer-reviewed journal, The Oncologist (Bruce A. Chabner, editor-in-chief), he is also the Founding Executive Editor of both Stem Cells (Jan Nolta, editor-in-chief), a 32-year-old journal of stem cell biology, and of the four-yearold journal, Stem Cells Translational Medicine (Anthony Atala, editor-in-chief). Dr. Murphy was founder and former CEO of the Hipple Cancer Research Center, NIH principal investigator and authored more than 150 peerreviewed papers. He is a Co-founder of the Society for Translational Oncology (Richard M. Goldberg & Patrick G. Johnston, co-chairs), he is a member of the Scientific Advisory Board of Hatteras Venture Partners (Herbert Boyer, chair), a charter member of the International Advisory Board of the VU University Medical Imaging Center, a charter member of Queen's University-Belfast School of Medicine International Review Board, Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), and Steering Committee Member and Senior Consultant of the Chinese Society of Clinical Oncology (CSCO).

Peter Paul Yu, MD, FACP, FASCO

Director, Cancer Research, Palo Alto Medical Foundation
Immediate Past President, ASCO
Palo Alto, California, USA

Dr. Yu received his medical degree from Brown University, and completed his internship and residency in Internal Medicine at St. Luke's-Roosevelt Hospital and a fellowship in neoplastic diseases at Mount Sinai Hospital. He was a Research Fellow and Associate at Memorial Sloan Kettering Cancer Center.

A medical oncologist and hematologist, Dr. Yu serves as the Director of Cancer Research at Palo Alto Medical Foundation, where he specializes in the treatment of solid tumors of the breast, brain, liver, lung, and prostate, as well as hematological malignancies including chronic leukemia, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma.

Dr. Yu is currently serving the American Society for Clinical Oncology (ASCO) as the organization's immediate Past President. He also serves on ASCO's Scientific Program, Nominating, Government Relations, and Special Awards Selection Committees.

In addition to his ASCO involvement, Dr. Yu is a member of the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B) as well as the Gynecologic Oncology Group. He is a Co-Chair of the Commission for the Certification of Health Information Technology Workgroups on Research and Oncology.

Prof. Lin QIU

Deputy Secretary General CSCO
Deputy Director of Harbin Institute of Hematology and Tumor, The 1st Hospital of Harbin

Prof. QIU received his PhD from the Medical College of the University of Tokyo and his post-doctoral degree from the University of Texas MD Anderson Cancer Center. Prof. QIU's academic interests mainly focus on the research of targeted therapy and biotherapy of leukemia.

Prof. QIU has published more than 27 peer-reviewed papers and 13 academic works. He also led more than 10 national-level research projects and has received several provincial scientific awards acknowledging his work. Prof. QIU now acts as a peer-reviewer for several journals and serves as an editor of the Chinese editions of the Journal of Clinical Oncology and The Oncologist.

Susan E. Bates, MD

Director, Translational Research, Columbia University Medical Center
New York, New York, USA

Dr. Susan Bates received her M.D. from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington, D.C., and in oncology at the National Cancer Institute (NCI). Dr. Bates has held positions of increasing responsibility at the NCI, receiving tenure in 1992. As Senior Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch at the NCI, her interests ranged from clinical to laboratory studies on drug resistance in T-cell lymphomas, breast cancer and renal cell cancer. Her Molecular Therapeutics Section is dedicated to new drug development, and finding antineoplastic agents that, alone or in combination with other anticancer agents, improve cancer therapy.

In August 2015, Dr. Bates joined Columbia University Medical Center in New York as Director of Translational Cancer Medicine. In this new position, Dr. Bates will seek to translate concepts from basic science to the clinic, and support the efforts of others in the same.

Dr. Bates and her Co-Editor, Dr. Tito Fojo, developed the Clinical Trial Results (CTR) section of The Oncologist to promote the global mission of sharing results of all clinical trials regardless of outcome. With more than 60 trials now published, CTR demonstrates that every trial, regardless of outcome, can have a benefit to the research community.

Mr. Xuexing Wang

Co-founder of Sinyoo Information Technology (Shanghai) Co. Ltd.

Mr. WANG is a member of the Precision Medical Treatment Association, a branch of the China Medicinal Biotech Association.

His research focuses on cancer data management and statistical analysis. His product, Crabyter® System, is now a leader among multiple domestic oncology data collaboration platforms. Crabyter® is a clinical oncology research data management platform and is used by more than 230 top clinical oncology departments, assisting experts in publishing more research results of greater influence.

He graduated from Nanjing Medical University and has both the clinician's license and the lawyer's license.